STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting

Mateusz Plucinski¹, Elizabeth A Ashley^{2

3}, Quique Bassat^{4

5

6

7

8}, Meera Venkatesan⁹, Philip J Rosenthal¹⁰, Eric Halsey¹

Affiliations

¹ U.S. President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia.
² Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane, Laos.
³ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
⁴ ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
⁵ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
⁶ ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain.
⁷ Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
⁸ Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
⁹ U.S. President's Malaria Initiative, United States Agency for International Development, Washington, District of Columbia.
¹⁰ University of California San Francisco, San Francisco, California.

Editorial

Mateusz Plucinski et al. Am J Trop Med Hyg. 2022.

. 2022 Jun 13;107(1):1-3.

doi: 10.4269/ajtmh.22-0224.

Mateusz Plucinski¹, Elizabeth A Ashley^{2

3}, Quique Bassat^{4

5

6

7

8}, Meera Venkatesan⁹, Philip J Rosenthal¹⁰, Eric Halsey¹

¹ U.S. President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia.
² Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane, Laos.
³ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
⁴ ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
⁵ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
⁶ ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain.
⁷ Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain.
⁸ Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
⁹ U.S. President's Malaria Initiative, United States Agency for International Development, Washington, District of Columbia.
¹⁰ University of California San Francisco, San Francisco, California.

No abstract available

Cited by

Therapeutic response to four artemisinin-based combination therapies in Angola, 2021.
Dimbu PR, Labuda S, Ferreira CM, Caquece F, André K, Pembele G, Pode D, João MF, Pelenda VM, Nieto Andrade B, Horton B, Kennedy C, Svigel SS, Zhou Z, Morais JFM, Rosário Jd, Fortes F, Martins JF, Plucinski MM. Dimbu PR, et al. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0152523. doi: 10.1128/aac.01525-23. Epub 2024 Feb 29. Antimicrob Agents Chemother. 2024. PMID: 38421163 Free PMC article.

1. World Health Organization , 2020. Report on Antimalarial Drug Efficacy, Resistance and Response: 10 Years of Surveillance (2010–2019). Geneva, Switzerland: World Health Organization.
1. World Health Organization , 2009. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva, Switzerland: World Health Organization.
1. World Health Organization , 2007. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva, Switzerland: World Health Organization.
1. World Health Organization , Informal Consultation on Methodology to Distinguish Reinfection from Recrudescence in High Malaria Transmission Areas. Available at: https://www.who.int/publications-detail-redirect/9789240038363.
1. Plucinski M, Hastings I, Moriarty LF, Venkatesan M, Felger I, Halsey ES, 2021. Variation in calculating and reporting antimalarial efficacy against Plasmodium falciparum in sub-Saharan Africa: a systematic review of published reports. Am J Trop Med Hyg 104: 1820–1829. - PMC - PubMed